Forest Laboratories, Inc.  

(Public, NYSE:FRX)   Watch this stock  
Find more results for FRX
0.0000
- Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.60
Shares 272.59M
Beta     -
Inst. own 89%
Jul 21, 2014
Q1 2015 Forest Laboratories, Inc. Earnings Release (Estimated)
Jun 17, 2014
Forest Laboratories, Inc. Special Shareholder Meeting
Apr 29, 2014
Q4 2014 Forest Laboratories, Inc. Earnings Conference Call
Apr 29, 2014
Q4 2014 Forest Laboratories, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2014
Net profit margin 4.95% 4.53%
Operating margin -2.55% 3.06%
EBITD margin - 17.65%
Return on average assets 2.06% 1.68%
Return on average equity 3.57% 2.78%
Employees 6,200 -
CDP Score - 56 E

Address

909 3rd Ave
NEW YORK, NY 10022-4731
United States - Map
+1-212-4217850 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company�s products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.